GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. reduced its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 16.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned 323,376 shares of the company’s stock after selling 62,044 shares during the quarter. Assenagon Asset Management S.A.’s holdings in GoodRx were worth $1,504,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in the stock. Fortem Financial Group LLC boosted its position in GoodRx by 7.2% during the 4th quarter. Fortem Financial Group LLC now owns 119,179 shares of the company’s stock valued at $554,000 after purchasing an additional 7,996 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of GoodRx by 358.7% during the third quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company’s stock valued at $169,000 after acquiring an additional 18,997 shares during the period. Franklin Resources Inc. acquired a new position in shares of GoodRx during the third quarter valued at $5,675,000. Sanctuary Advisors LLC bought a new position in shares of GoodRx during the third quarter worth about $85,000. Finally, Barclays PLC increased its holdings in shares of GoodRx by 1,316.1% in the 3rd quarter. Barclays PLC now owns 140,113 shares of the company’s stock worth $973,000 after acquiring an additional 130,219 shares during the period. 63.77% of the stock is owned by institutional investors.

GoodRx Trading Up 4.7 %

GoodRx stock opened at $4.93 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The firm has a market cap of $1.88 billion, a price-to-earnings ratio of -164.33, a price-to-earnings-growth ratio of 2.38 and a beta of 1.27. The firm’s 50 day moving average price is $4.59 and its two-hundred day moving average price is $6.37. GoodRx Holdings, Inc. has a 1 year low of $4.09 and a 1 year high of $9.26.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on GDRX shares. KeyCorp reduced their target price on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Barclays cut their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Morgan Stanley decreased their price target on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 17th. Citigroup cut their price objective on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research note on Friday, January 10th. Finally, Mizuho initiated coverage on shares of GoodRx in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 target price for the company. Five research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, GoodRx has an average rating of “Moderate Buy” and an average price target of $8.38.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.